Germany
About Biotest Aktiengesellschaft
Biotest Aktiengesellschaft is a biopharmaceutical company specializing in the development, manufacturing, and sale of biological and biotechnological pharmaceutical products. Headquartered in Dreieich, Germany, the company operates globally, with a focus on clinical immunology, haematology, and intensive care medicine.
Business Segments
- European Union
- Rest of the World
- Stateless
Key Products
- Haemoctin & Vihuma – Treatment for haemophilia A.
- Haemonine – Treatment for haemophilia B.
- Cytotect CP biotest – For cytomegalovirus infections.
- Fovepta – Immunoprophylaxis of hepatitis B in neonates.
- Hepatect – Prophylaxis of hepatitis B reinfection.
- Intratect & Yimmugo – For immune deficiency syndromes and autoimmune diseases.
- Varitect – Treatment for varicella zoster virus infections.
- Zutectra – Hepatitis B immunoglobulins.
- Albiomin & Biseco – Blood volume restoration.
- Cofact – For coagulation factor deficiencies.
- Fibrinogen – Treatment for congenital fibrinogen deficiency.
- Trimodulin – For community-acquired pneumonia and COVID-19.
- Pentaglobin – Treatment for bacterial infections.
Corporate Background
Founded in 1946 as Biotest Serum-Institut GmbH, the company rebranded as Biotest Aktiengesellschaft in 1986. Today, it operates as a subsidiary of Grifols Biotest Holdings GmbH.